血清镁水平升高提示接受免疫检查点抑制剂治疗的癌症患者预后良好
这项多中心回顾性研究纳入2012年8月至2023年5月在三家大型癌症中心接受免疫检查点抑制剂(ICB)治疗的泛癌种患者1441例,包括肺癌1042例、食管癌270例和霍奇金淋巴瘤129例。以血清镁0.79 mmol/L为最佳截断值分组,高镁组(Mg2+ ≥ 0.79 mmol/L)在三个肿瘤队列中均较低镁组(Mg2+ < 0.79 mmol/L)有更长的无进展生存期(PFS)和总生存期(OS),多因素分析证实血清镁水平是独立预后因素。作者结论认为高血清镁水平患者临床结局显著更好,但需进一步前瞻性验证研究确认。
要点
- 高镁组(Mg2+ ≥ 0.79 mmol/L)在肺癌、食管癌和霍奇金淋巴瘤队列中PFS和OS均较低镁组(Mg2+ < 0.79 mmol/L)延长。
- 单因素和多因素分析证实血清镁水平是接受ICB治疗癌症患者的独立预后因素。
- 作者指出需进一步前瞻性验证研究确认上述发现。
核心结论
- 多中心研究显示,接受ICB治疗的患者中,血清镁水平升高者较高镁水平低者临床结局显著更好。
- 作者指出需进一步前瞻性验证研究确认这些发现。
研究设计与样本
- 多中心回顾性研究,纳入2012年8月至2023年5月在三家大型癌症中心接受ICB治疗的泛癌种患者1441例,包括肺癌1042例、食管癌270例和霍奇金淋巴瘤129例。
- 主要目标为评估血清镁水平与ICB治疗反应的相关性,并进一步评估血清镁水平与无进展生存期(PFS)和总生存期(OS)的关联。
主要发现
- 血清镁水平最佳截断值为0.79 mmol/L,据此将患者分为高镁组(Mg2+ ≥ 0.79 mmol/L)和低镁组(Mg2+ < 0.79 mmol/L)。
- 在三个肿瘤队列中,高镁组患者PFS和OS均较低镁组患者延长。
- 单因素和多因素分析证实血清镁水平是接受ICB治疗癌症患者的独立预后因素。
关键数值与推荐
- 血清镁水平最佳截断值为0.79 mmol/L。
- 高镁组定义为Mg2+ ≥ 0.79 mmol/L,低镁组定义为Mg2+ < 0.79 mmol/L。
局限性
- 作者指出需进一步前瞻性验证研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnesium deficiency influences the activation and cytotoxicity of immune cells. Nevertheless, whether serum magnesium levels influence the clinical outcomes of immune checkpoint blockers (ICBs) treatment still remains ambiguous. There is an urgent need for clinical research to elucidate the relationship between serum magnesium levels and the outcomes of ICB therapy. Such insights could offer new perspectives on immunotherapy for cancer. METHODS: A multi-center retrospective study involving in pan-cancer patients treated with ICBs at three large cancer centers from August 2012 to May 2023 was conducted. The primary objective was to assess the correlation between serum magnesium levels and therapeutic response in patients receiving ICBs, and further evaluate the associations between serum magnesium levels and progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 1441 patients treated with ICBs, including 1042 with lung cancer, 270 with esophageal cancer, and 129 with Hodgkin lymphoma, were enrolled in this study. We found that patients with elevated serum magnesium levels exhibited a favourable response to ICBs treatment. The optimal cut-off point for serum magnesium level (0.79 mmol/L) was applied for stratifying patients into distinct groups. In the three tumor cohorts, patients in high magnesium level group (Mg2+ ≥ 0.79 mmol/L) had longer PFS and OS than those in low magnesium level group (Mg2+ < 0.79 mmol/L). Univariate and multivariate analyses confirmed that the serum Mg2+ level serves as an independent prognostic factor for cancer patients receiving ICBs therapy. CONCLUSION: Our multi-center study demonstrated that among patients receiving ICBs therapy, those with elevated serum magnesium levels exhibit significantly better clinical outcomes than those with low serum magnesium levels. Further prospective validation studies are needed to confirm these findings.
引用
- Feng Y, Gao M, Xu X, et al. Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers. Eur J Cancer. 2024. PMID: 39489925. doi:10.1016/j.ejca.2024.115069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。